Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies

Next Previous
Trial Profile

A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GS 0321 (Primary) ; Zimberelimab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Compugen

Most Recent Events

  • 06 Oct 2025 According to a Compugen Ltd. media release, company announced poster presentation from this study will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place on : Friday, November 7, 2025, in National Harbor, Maryland.
  • 08 Jan 2025 According to a Compugen Ltd. media release, company announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead.
  • 29 Jul 2024 According to a Compugen Ltd. media release, In 2023, Compugen and Gilead entered into a license agreement, pursuant to which Gilead was granted exclusive rights to develop and commercialize, COM503. The FDA IND clearance for COM503 triggers a $30 million milestone payment from company's partner Gilead to initiate Phase 1 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top